Trust Co. of Oklahoma Sells 1,409 Shares of Zoetis Inc. (NYSE:ZTS)

Trust Co. of Oklahoma trimmed its position in Zoetis Inc. (NYSE:ZTS) by 16.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,947 shares of the company’s stock after selling 1,409 shares during the period. Trust Co. of Oklahoma’s holdings in Zoetis were worth $1,132,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Mizuho Securities USA LLC boosted its stake in Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares during the period. International Assets Investment Management LLC raised its holdings in shares of Zoetis by 41,235.7% in the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock valued at $183,652,000 after acquiring an additional 937,700 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Zoetis by 296.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after acquiring an additional 665,331 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Zoetis by 38.3% during the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after purchasing an additional 572,511 shares in the last quarter. Finally, Holocene Advisors LP bought a new position in shares of Zoetis in the third quarter worth approximately $110,809,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $166.64 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a market capitalization of $75.18 billion, a P/E ratio of 31.32, a PEG ratio of 2.58 and a beta of 0.89. The stock has a 50 day moving average price of $170.39 and a two-hundred day moving average price of $179.80.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the prior year, the company posted $1.36 EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. Zoetis’s dividend payout ratio is presently 37.59%.

Analyst Ratings Changes

ZTS has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.